Type of Cancer
Phase
Division (Location)
Study ID
NCT#
Brief Description
A Phase 1, Open-Label, Dose-Escalation and Cohort Expansion First-in-Human Study of the Safety, Tolerability, Activity and Pharmacokinetics of REGN3767 (anti-LAG-3 mAb) Administered Alone or in Combination with REGN2810 (anti-PD-1 mAb) in Patients with Advanced Malignancie
To find out more about this clinical trial, or to schedule an appointment, call (201) 518-3587.